New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePNC-27 vs GHRP-2

PNC-27 vs GHRP-2

Side-by-side comparison of key properties, dosing, and research.

Immune Support
PNC-27
Growth Hormone Peptides
GHRP-2
Summary
PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
GHRP-2 is a potent synthetic hexapeptide that stimulates growth hormone release by activating ghrelin receptors in the pituitary and hypothalamus. It produces one of the strongest GH pulses among GHRPs, though unlike Ipamorelin it does cause modest increases in cortisol and prolactin.
Half-Life
Not well established; estimated minutes to hours
15–60 minutes
Admin Route
Intravenous (research), Intraperitoneal (research)
SubQ, Intranasal
Research
Typical Dose
Not established for humans; research doses vary by cell line and model
100–300 mcg
Frequency
Not established for human use
2–3 times daily
Key Benefits
  • Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
  • Spares normal cells lacking surface HDM2 expression
  • Membranolytic mechanism bypasses intracellular resistance pathways
  • Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
  • Potential for combination with conventional chemotherapy
  • Novel non-genotoxic anticancer mechanism
  • Strong GH pulse stimulation
  • Increased IGF-1 levels
  • Enhanced muscle growth and recovery
  • Improved fat metabolism
  • Better sleep quality
  • Increased bone density
  • Enhanced appetite (less pronounced than GHRP-6)
  • Anti-aging effects via GH axis optimization
Side Effects
  • Limited human clinical data; largely in vitro and animal studies
  • Potential immunogenic reactions (foreign peptide)
  • Systemic toxicity at high doses not well characterized
  • Unknown interactions with current chemotherapy agents
  • Increased appetite
  • Water retention
  • Elevated cortisol (modest)
  • Elevated prolactin (modest)
  • +2 more
Stacks With